

**Opto Circuits' subsidiary enters Indian market with PTCA combination device  
- Company gets DCGI registration for "MAGICAL™" –**

**Bengaluru, India | Bonn, Germany  
December 6, 2010**

Opto Circuits (India) Limited's wholly-owned subsidiary, Eurocor GmbH, has received registration from Drug Controller General of India (DCGI) for its PTCA (Percutaneous Transluminal Coronary Angioplasty) Drug-Coated Stent delivery Balloon, MAGICAL™. The procedure using MAGICAL™ involves the introduction of a drug (paclitaxel) coated balloon into the target coronary vessel, release of the drug on balloon inflation and deployment of a cobalt chromium bare metal stent to keep the vessel open. This is a drug involving combination device (DEB; Drug Eluting Balloon + BMS; Bare Metal Stent) to have entered the Indian market that treats coronary indications with a stent and a balloon, with an objective to effectively deter the occurrence of restenosis and late stent thrombosis, two perilous risks associated with regular angioplasty treatments.

MAGICAL™ is ideal for "High Risk Patients", who may have to face a surgical operation and for "Non-Compliant Patients" those, who do not follow the prescription of a physician. The greatest clinical advantage is limited need for anti-platelet therapy post treatment which provides better life quality after stenting.

Coronary Angioplasty (PTCA) is a widely used method of treating patients with blocked arteries. Until recently the most recurring problem for the long-term durability of angioplasty was restenosis (re-closure of the affected artery). Drug-eluting stents (DES) and drug-eluting balloons (DEB) have markedly minimized this situation of restenosis, however DES may be susceptible to an event known as "late stent thrombosis", where the blood-clotting inside the stent can occur one or more years post-stenting. MAGICAL™ stenting eliminates the risk of late stent thrombosis as there is no synthetic polymer coating on the stent. There is no long-term drug associated late adverse effect potential.

MAGICAL™ – The Paclitaxel delivery Cobalt Chromium stent system provides the thinnest stent strut design (0.0025") for rapid healing. This is an option to significantly enhance the long-term quality of patient treatment. While the MAGICAL™ stent is expanded and deployed into the arterial wall at the lesion site, the stent delivery balloon is kept inside the expanded stent, inflated up to one minute for an optimal drug release to the coronary artery lesion. Paclitaxel is absorbed by the arterial wall at the lesion site.